Fate Therapeutics wins $15 million CIRM grant for lupus trial
AI Summary- Fate Therapeutics received a CIRM grant supporting its RECLAIM-LN lupus nephritis trial.
- $15.0 million will fund development of FT819, an off-the-shelf CAR T-cell therapy.
- RECLAIM-LN is expected to enroll approximately 53 patients refractory to two prior immunosuppressive therapies.